{"id":"W1851335480","doi":"10.1093/annonc/mdv262.06","title":"LBA-06 INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib (REG) in refractory advanced oesophagogastric cancer (AOGC) - A study by the Australasian Gastrointestinal Trials Group (AGITG): Final overall and subgroup results","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University Health Centre; Saint John Regional Hospital","funders":"","keywords":"Medicine; Internal medicine; Clinical endpoint; Placebo; Gastroenterology; Refractory (planetary science); Population; Adverse effect; Phases of clinical research; Ramucirumab; Progression-free survival; Regorafenib; Cancer; Randomized controlled trial; Surgery; Clinical trial; Overall survival; Colorectal cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002521728,0.003221033,0.006351575,0.0008727338,0.0006922095,0.001776619,0.001742634,0.002683203,0.01344778],"category_scores_gemma":[0.002754169,0.001253918,0.00405471,0.0007599736,0.001603534,0.001787362,0.0006016418,0.005828731,0.003246443],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007995192,"about_ca_system_score_gemma":0.001752474,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00132909,"about_ca_topic_score_gemma":0.003444775,"domain_scores_codex":[0.9991278,0.0004527832,0.00007580272,0.0001550762,0.00006795587,0.0001205806],"domain_scores_gemma":[0.9991818,0.0002159886,0.0001801821,0.00009946618,0.00006965759,0.0002527796],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9738927,0.003307059,0.0003298397,0.001952701,0.003447673,0.00003266309,0.00004369329,0.0002906741,0.002080357,0.0001645006,0.001995984,0.01246219],"study_design_scores_gemma":[0.988972,0.009233765,0.0003400134,0.00002642629,0.0006176604,0.00001271681,0.00001007495,0.00009556664,0.0001263845,0.00006466257,0.0004917234,0.000009021121],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9004536,0.03928275,0.004780562,0.003866792,0.004063912,0.0220867,0.01224625,0.002098015,0.01112139],"genre_scores_gemma":[0.928031,0.0182296,0.006679252,0.005695479,0.001841622,0.01877973,0.007800804,0.0002514562,0.01269107],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01344778,"threshold_uncertainty_score":0.04498732,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1817062739814543,"score_gpt":0.451046677039902,"score_spread":0.2693404030584478,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}